Headquartered in Gaithersburg, MD·Fiscal year ends December·NASDAQ: NVAX·novavax.com
About Novavax
Novavax, Inc. is a vaccine company whose technology platform combines protein-based nanoparticles with its proprietary Matrix-M saponin-based adjuvant. Its strategy rests on three pillars: partnering its technology, targeted and capital-efficient R&D, and a lean operating model.
Its marketed products are the COVID-19 vaccine Nuvaxovid and the R21/Matrix-M malaria vaccine. Commercial leadership of Nuvaxovid has moved to partners:
- Sanofi leads in the U.S. and select markets under a co-exclusive license.
- Takeda covers Japan.
- Serum Institute of India co-formulates and fills product.
Novavax's revenue now comes from several partner-related sources:
- Supply sales of finished product and Matrix-M adjuvant to partners.
- Royalties: high teens to low twenties percent on Sanofi's Nuvaxovid sales, and high single digits to sub-teens percent on Sanofi CIC products.
- Milestones, including a pending $75 million technology-transfer milestone and a $225 million U.S. CIC launch milestone.
- R&D reimbursement and licensing deals with partners including Pfizer and Serum.
Its internal pipeline includes a preclinical C. difficile vaccine expected to enter the clinic as early as 2027. Novavax is also exploring Matrix-M in other infectious diseases and oncology to create further licensing opportunities. Updated
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.…
Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands…
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide…
A protein-vaccine developer with no fresh catalyst just posted a double-digit gain that dwarfs what Moderna and Merck managed in the same session, and the explanation reveals something uncomfortable about how this…
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX),…
Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that leaves Moderna and BioNTech looking like bystanders. The real question is…
Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a…
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already…
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA | MRNA Price Prediction) has fallen 58.2% over five years. BioNTech (NASDAQ: BNTX) is down 10.9%…
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Thursday's top analyst upgrades and downgrades included Bumble, Coupang, Datadog, Dish Network, DraftKings, Eli Lilly, International Flavors & Fragrances, LivePerson, Novavax, Nvidia, Qualcomm and Rivian Automotive.
Novavax, Inc. is a vaccine company whose technology platform combines protein-based nanoparticles with its proprietary Matrix-M saponin-based adjuvant. Its strategy rests on three pillars: partnering its technology, targeted and capital-efficient R&D, and a lean operating model.
What is the NVAX stock price target?
The Wall Street consensus 12-month price target for NVAX is $14.11.